Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO 2019 Congress

Update on novel therapies in ovarian cancer

Where do we stand with PARP inhibitors in ovarian cancer treatment in 2019?

Date

29 Sep 2019

Session

Update on novel therapies in ovarian cancer

Topics

Tumour Site

Ovarian Cancer

Presenters

Jonathan Ledermann

Authors

J.A. Ledermann

Author affiliations

  • Cancer Trials Centre, University College London Cancer Institute, WC1E6BT - London/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.